-
Mashup Score: 3
Background: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy h…
Source: journals.sagepub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1USPSTF Recommends Breast Cancer Screening Starting at Age 40 - 19 hour(s) ago
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1USPSTF Recommends Breast Cancer Screening Starting at Age 40 - 2 day(s) ago
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Although immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast cancer settings has fallen short.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically significant and clinically meaningful improvement in PFS
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically significant and clinically meaningful improvement in PFS
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically significant and clinically meaningful improvement in PFS
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
TROPION-Breast03: datopotamab deruxtecan ± durvalumab in pts with triple-negative breast cancer and residual invasive disease after neoadjuvant therapy - study design published in TAMO. Trial actively enrolling @SWOG #bcsm Full text link: https://t.co/pawRZYBKlm